

JAK selectivity or GUT selectivity for IBD treatment

Steering Committee

Silvio Danese, Laurent Peyrin-Biroulet

Inflammatory bowel disease (IBD) including Crohn's Disease (CD) and Ulcerative Colitis (UC) are chronic diseases that significantly impact on patients' lives. Novel diagnostic and interventional techniques, imaging modalities and the introduction of biologics and small molecule have dramatically improved their management and outcomes.

The main aim of these webinars is to focus the attention of practicing IBD experts on the most novel imaging modalities, the use of new drugs, and how to integrate them in daily clinical practice.

Several interactive clinical cases will be presented and discussed to deliver the learning objectives.

FACULTY

Silvio Danese

Head IBD Center, Professor of Gastroenterology
Humanitas Research and University Hospital Rozzano, Milan, Italy

Laurent Peyrin-Biroulet

Full Professor of Medicine IBD Unit
Department of Gastroenterology Nancy University Hospital, France

Edouard Louis

Professor and Head of the Gastroenterology
department at Liège University Hospital CHU Liege, Belgium

Iris Dotan

Division of Gastroenterology
Rabin Medical Center, Petah Tikva, Israel
The Sackler Faculty of Medicine, Tel Aviv University, Israel

- **Welcome and Intro of meeting objectives 5'**
- Laurent Peyrin-Biroulet, France
- **Difficult clinical case discussion 20'**
- Eduard Louis, Belgium
- **Difficult clinical case discussion 20'**
- Iris Dotan, Israel
- **LECTURE**
- **Clinical Relevance of JAK inhibitor selectivity in IBD 15'**
- Silvio Danese, Italy

FOR REGISTRATION CLICK HERE

SPONSORED BY

Theravance Biopharma 
Medicines That Make a Difference®



ORGANIZING SECRETARIAT

Materia Prima srl

Phone +39 3457238692

www.materia1a.it - segreteria@materia1a.it